Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewise Therapeutics, Inc. (NASDAQ: EWTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Edgewise is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and serious cardiac conditions, and its filings offer detailed information on clinical progress, financial results, and corporate governance.
Investors can review current reports on Form 8-K that Edgewise files to announce material events, such as clinical data updates for sevasemten in Becker and Duchenne muscular dystrophies, progress in the EDG-7500 CIRRUS-HCM Phase 2 trial in hypertrophic cardiomyopathy, and initiation of Phase 1 studies for EDG-15400 in heart failure. Other 8-K filings describe financial results for specific quarters, appointments of new directors and executive officers, and equity-based compensation arrangements, including inducement grants under Nasdaq Listing Rule 5635(c)(4).
Through this page, users can also locate references to annual and quarterly reports (Forms 10-K and 10-Q) and related exhibits, where Edgewise discusses risk factors, liquidity, research and development expenses, and dependence on key product candidates such as sevasemten and EDG-7500. Disclosures frequently highlight that the company is clinical-stage, has not generated product revenue, and faces the typical uncertainties of drug development and regulatory approval.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand clinical, financial, and governance information. Users can also track insider and equity-related disclosures reported in 8-K exhibits and other filings to see how leadership and directors are compensated and how the company structures its incentive plans.
Edgewise Therapeutics Director Arlene Morris received a stock option grant on June 16, 2025, representing a significant insider transaction. The key details of this Form 4 filing include:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule aligns with typical board member equity compensation structures. The filing was completed by Attorney-in-Fact John R. Moore on June 18, 2025.
Edgewise Therapeutics (EWTX) reported a Form 4 filing disclosing insider trading activity by Director Jonathan D. Root. On June 16, 2025, Root was granted 30,000 stock options with the following key terms:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership type: Direct
The stock options represent the right to purchase 30,000 shares of Edgewise Therapeutics common stock. The transaction was executed under standard compensation arrangements for directors, with zero cost basis for the options grant. The filing was completed by John R. Moore as attorney-in-fact for Jonathan Root on June 18, 2025.
Peter A. Thompson, who serves as both Director and 10% Owner of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest 100% on the earlier of:
- June 16, 2026, or
- The business day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
The transaction was reported via Form 4 filing, signed by John R. Moore as attorney-in-fact for Peter Thompson on June 18, 2025. This equity compensation grant aligns with standard director compensation practices and represents a long-term incentive structure with a one-year cliff vesting period.